USPTO serial 85710504
LEAFBIO
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- May 31, 2016
- Examiner
- WILKE, JOHN
- Law office
- TMEG LAW OFFICE 104
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with LEAFBIO?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,097*
Plus Government fees of $2,550
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
San Diego, CA
San Diego, CA
San Diego, CA
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Paul Nardulli
Paul Nardulli OPTIMA LAW GROUP, APC4275 Executive Square, Suite 200La Jolla, CA 92037UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Diagnostic reagents for scientific or research use; [ Diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents to monitor toxicity of drugs; ] Diagnostic reagents for clinical or medical laboratory use; [ Diagnostic reagents for in vitro use in biochemistry, clinical chemistry and microbiology; ] Diagnostic reagents for scientific or research use; Laboratory chemicals, namely, an antibody reagent used for the detection of antigens in cell and tissue analysis for in vitro diagnostic use; [ Reagent for chemical analysis; ] Reagents for research purposes; Reagents for scientific or medical research use; [ Reagents for testing the sterility of pharmaceuticals and injectable solutions; ] Reagents for use in scientific apparatus for chemical or biological analysis; Reagents for use in biodefense | ACTIVE | Jan 1, 2013 |
| 005 | Pharmaceutical products for use in the treatment and prevention of [ cardiovascular diseases and disorders, central nervous system and neurological diseases and disorders, urological diseases and disorders, ] viral and infectious diseases, [ cancer, gastrointestinal diseases and disorders, musculoskeletal diseases and disorders, migraines and headaches, pain, hypertension, ] inflammation and inflammatory diseases and disorders, [ metabolic diseases and disorders, ] respiratory and infectious diseases and disorders, immunological, bacterial, viral and fungal diseases and disorders, [ psychiatric diseases and disorders, asthma, allergies, diabetes, obesity, stroke, erectile and sexual dysfunction, ] sexually transmitted infections including, but not limited to, HIV, HPV, and herpes [, and hemolytic diseases and disorders; Pharmaceutical preparations, namely, cholesterol preparations, osteoporosis preparations, oncological preparations, dermatological preparations, urological preparations, ophthalmologic preparations, tissue and skin repair preparations and gynecological preparations ] ; Pharmaceuticals, namely, anti-infectives; [ Diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; Medical diagnostic reagents; Medical diagnostic reagents and assays for testing of body fluids, including for microorganisms; Drug delivery agents consisting of compounds that facility delivery of a wide range of pharmaceuticals; ] Antibacterial pharmaceuticals; [ Cardiovascular pharmaceuticals; ] Contraceptive foams, sponges, preparations; [ Oral contraceptives; ] Pharmaceutical products for use in biodefense | ACTIVE | Jan 1, 2013 |
| 042 | Pharmaceutical research and development; research and development of pharmaceutical preparations for the treatment and prevention of [ cardiovascular diseases and disorders, central nervous system and neurological diseases and disorders, ] viral and infectious diseases, [ cancer, urological diseases and disorders, ] gastrointestinal diseases and disorders, [ musculoskeletal diseases and disorders, migraines and headaches, pain, hypertension, ] inflammation and inflammatory diseases and disorders, [ metabolic diseases and disorders, ] respiratory and infectious diseases and disorders, immunological, bacterial, viral and fungal diseases and disorders, [ psychiatric diseases and disorders, asthma, allergies, diabetes, obesity, stroke, erectile and sexual dysfunction, ] sexually transmitted infections including, but not limited to, HIV, HPV, and herpes [ and hemolytic diseases and disorders; research and development of pharmaceutical preparations, namely, cholesterol preparations, osteoporosis preparations, oncological preparations, dermatological preparations, urological preparations, ophthalmologic preparations, tissue and skin repair preparations and gynecological preparations ] ; research and development of drug delivery devices; medical and scientific research, namely, conducting clinical trials; Consulting services in the fields of biotechnology, pharmaceutical research and development, [ laboratory testing, diagnostics, ] and pharmacogenetics; Development of pharmaceutical preparations and medicines; Pharmaceutical drug development; Pharmaceutical research and development services; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; [ Providing reagent sample testing and diagnostic services for others in the fields of science and research related thereto; ] Pharmaceutical research and development in relation to biodefense | ACTIVE | Jan 1, 2013 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by LeafBio, Inc.
- Other trademarks owned by LeafBio, Inc.
- Other trademarks owned by LeafBio, Inc.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named LEAFBIO
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 1, 2025 | REM2 | COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED | — |
| Nov 30, 2022 | NA85 | NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED | — |
| Nov 30, 2022 | C15A | REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK. | — |
| Nov 17, 2022 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| May 12, 2022 | E815 | TEAS SECTION 8 & 15 RECEIVED | — |
| May 31, 2016 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Apr 26, 2016 | SUNA | NOTICE OF ACCEPTANCE OF STATEMENT OF USE MAILED | — |
| Apr 23, 2016 | CNPR | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | — |
| Apr 16, 2016 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Mar 17, 2016 | IUAF | USE AMENDMENT FILED | — |
| Mar 17, 2016 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| Sep 29, 2015 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST MAILED | — |
| Sep 27, 2015 | EX5G | SOU EXTENSION 5 GRANTED | — |
| Sep 9, 2015 | EXT5 | SOU EXTENSION 5 FILED | — |
| Sep 9, 2015 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Apr 4, 2015 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST MAILED | — |
| Apr 3, 2015 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Mar 20, 2015 | EXT4 | SOU EXTENSION 4 FILED | — |
| Mar 20, 2015 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Oct 2, 2014 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST MAILED | — |
| Oct 1, 2014 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Sep 19, 2014 | EXT3 | SOU EXTENSION 3 FILED | — |
| Sep 19, 2014 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jun 3, 2014 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Apr 18, 2014 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST MAILED | — |
| Apr 17, 2014 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Apr 14, 2014 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Mar 20, 2014 | EXT2 | SOU EXTENSION 2 FILED | — |
| Mar 20, 2014 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Sep 26, 2013 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST MAILED | — |
| Sep 24, 2013 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Sep 24, 2013 | EXT1 | SOU EXTENSION 1 FILED | — |
| Sep 24, 2013 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Mar 26, 2013 | NOAM | NOA MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jan 29, 2013 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 9, 2013 | NPUB | NOTICE OF PUBLICATION | — |
| Dec 17, 2012 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 15, 2012 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 31, 2012 | MPMK | NOTICE OF PSEUDO MARK MAILED | — |
| Aug 30, 2012 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 25, 2012 | NWAP | NEW APPLICATION ENTERED | — |